150 related articles for article (PubMed ID: 28188251)
1. Population Impact & Efficiency of Benefit-Targeted Versus Risk-Targeted Statin Prescribing for Primary Prevention of Cardiovascular Disease.
Pletcher MJ; Pignone M; Jarmul JA; Moran AE; Vittinghoff E; Newman T
J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28188251
[TBL] [Abstract][Full Text] [Related]
2. Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease.
Thanassoulis G; Williams K; Altobelli KK; Pencina MJ; Cannon CP; Sniderman AD
Circulation; 2016 Apr; 133(16):1574-81. PubMed ID: 26945047
[TBL] [Abstract][Full Text] [Related]
3. A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention.
Thanassoulis G; Sniderman AD; Pencina MJ
JAMA Cardiol; 2018 Nov; 3(11):1090-1095. PubMed ID: 30422172
[TBL] [Abstract][Full Text] [Related]
4. Statin Use in Primary Prevention of Atherosclerotic Cardiovascular Disease According to 5 Major Guidelines for Sensitivity, Specificity, and Number Needed to Treat.
Mortensen MB; Nordestgaard BG
JAMA Cardiol; 2019 Nov; 4(11):1131-1138. PubMed ID: 31577339
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk.
Kohli-Lynch CN; Bellows BK; Thanassoulis G; Zhang Y; Pletcher MJ; Vittinghoff E; Pencina MJ; Kazi D; Sniderman AD; Moran AE
JAMA Cardiol; 2019 Oct; 4(10):969-977. PubMed ID: 31461121
[TBL] [Abstract][Full Text] [Related]
6. Comparing eligibility for statin therapy for primary prevention under 2022 USPSTF recommendations and the 2018 AHA/ACC/ multi-society guideline recommendations: From National Health and Nutrition Examination Survey.
Gupta K; Kakar TS; Jain V; Gupta M; Al Rifai M; Slipczuk L; Nambi V; Bittner V; Blumenthal RS; Stone NJ; Lavie CJ; Virani SS
Prog Cardiovasc Dis; 2022; 75():78-82. PubMed ID: 36038004
[TBL] [Abstract][Full Text] [Related]
7. Novel method versus the Friedewald method for estimating low-density lipoprotein cholesterol in determination of the eligibility for statin treatment for primary prevention in the United States.
Shin D; Bohra C; Kongpakpaisarn K
Medicine (Baltimore); 2018 Apr; 97(17):e0612. PubMed ID: 29703063
[TBL] [Abstract][Full Text] [Related]
8. Implications of American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Guidelines on Statin Underutilization for Prevention of Cardiovascular Disease in Diabetes Mellitus Among Several US Networks of Community Health Centers.
Akhabue E; Rittner SS; Carroll JE; Crawford PM; Dant L; Laws R; Leo MC; Puro J; Persell SD
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28673901
[TBL] [Abstract][Full Text] [Related]
9. Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk by Statin Use in U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007-2014.
Fan W; Philip S; Granowitz C; Toth PP; Wong ND
Diabetes Care; 2019 Dec; 42(12):2307-2314. PubMed ID: 31575639
[TBL] [Abstract][Full Text] [Related]
10. Statin Eligibility in Primary Prevention: From a Risk-Based Strategy to a Personalized Approach Based on the Predicted Benefit.
Cesena FHY; Laurinavicius AG; Valente VA; Conceição RD; Nasir K; Santos RD; Bittencourt MS
Am J Cardiol; 2018 Jun; 121(11):1315-1320. PubMed ID: 29605080
[TBL] [Abstract][Full Text] [Related]
11. Assessing potential population impact of statin treatment for primary prevention of atherosclerotic cardiovascular diseases in the USA: population-based modelling study.
Yang Q; Zhong Y; Gillespie C; Merritt R; Bowman B; George MG; Flanders WD
BMJ Open; 2017 Jan; 7(1):e011684. PubMed ID: 28119384
[TBL] [Abstract][Full Text] [Related]
12. Use of Statins for Primary Prevention: Selection of Risk Threshold and Implications Across Race and Gender.
Goyal A; Cooper HA; Aronow WS; Nagpal P; Yandrapalli S; Nabors CC; Frishman WH
Am J Med; 2018 Oct; 131(10):1234-1237. PubMed ID: 29928863
[TBL] [Abstract][Full Text] [Related]
13. Effects of Race on Statin Prescribing for Primary Prevention With High Atherosclerotic Cardiovascular Disease Risk in a Large Healthcare System.
Dorsch MP; Lester CA; Ding Y; Joseph M; Brook RD
J Am Heart Assoc; 2019 Nov; 8(22):e014709. PubMed ID: 31707943
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012.
Wong ND; Young D; Zhao Y; Nguyen H; Caballes J; Khan I; Sanchez RJ
J Clin Lipidol; 2016; 10(5):1109-18. PubMed ID: 27678427
[TBL] [Abstract][Full Text] [Related]
15. Atherosclerotic cardiovascular disease risk assessment and predictors of statin use in Filipino-American Women.
Borja-Hart N; Graff JC; Nolan VG; Wang J; Cooper-DeHoff RM; Ancheta IB
J Clin Pharm Ther; 2019 Aug; 44(4):632-639. PubMed ID: 30963623
[TBL] [Abstract][Full Text] [Related]
16. Primary Prevention With Statins: ACC/AHA Risk-Based Approach Versus Trial-Based Approaches to Guide Statin Therapy.
Mortensen MB; Afzal S; Nordestgaard BG; Falk E
J Am Coll Cardiol; 2015 Dec; 66(24):2699-2709. PubMed ID: 26700832
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines.
Pagidipati NJ; Navar AM; Mulder H; Sniderman AD; Peterson ED; Pencina MJ
JAMA; 2017 Apr; 317(15):1563-1567. PubMed ID: 28418481
[TBL] [Abstract][Full Text] [Related]
18. Statin Therapy: Diabetes Mellitus Risk and Cardiovascular Benefit in Primary Prevention.
Porath A; Arbelle JE; Fund N; Cohen A; Mosseri M
Isr Med Assoc J; 2018 Aug; 20(8):480-485. PubMed ID: 30084572
[TBL] [Abstract][Full Text] [Related]
19. Low-density lipoprotein-cholesterol lowering in individuals at intermediate cardiovascular risk: Percent reduction or target level?
Cesena FHY; Laurinavicius AG; Valente VA; Conceição RD; Santos RD; Bittencourt MS
Clin Cardiol; 2018 Mar; 41(3):333-338. PubMed ID: 29574925
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France.
Giral P; Neumann A; Weill A; Coste J
Eur Heart J; 2019 Nov; 40(43):3516-3525. PubMed ID: 31362307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
